These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 36931078

  • 1. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T.
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T.
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [Abstract] [Full Text] [Related]

  • 3. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 4. No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP).
    Butzkueven H, Kappos L, Spelman T, Trojano M, Wiendl H, Su R, Liao S, Hyde R, Licata S, Ho PR, Campbell N.
    Ther Adv Neurol Disord; 2021 Jul; 14():17562864211042458. PubMed ID: 34603507
    [Abstract] [Full Text] [Related]

  • 5. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ, Naismith RT, Krupp LB, Charvet LE, Liao S, Fisher E, de Moor C, Williams JR, Campbell N.
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [Abstract] [Full Text] [Related]

  • 6. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ.
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.
    BMC Neurol; 2019 Jun 08; 19(1):116. PubMed ID: 31176355
    [Abstract] [Full Text] [Related]

  • 8. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, ASCEND investigators.
    Lancet Neurol; 2018 May 08; 17(5):405-415. PubMed ID: 29545067
    [Abstract] [Full Text] [Related]

  • 9. Erratum.
    Mult Scler; 2016 Oct 08; 22(12):NP9-NP11. PubMed ID: 26041800
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Tysabri® Observational Program (TOP) Investigators.
    Mult Scler Relat Disord; 2018 Aug 08; 24():11-19. PubMed ID: 29860197
    [Abstract] [Full Text] [Related]

  • 11. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D.
    Eur J Neurol; 2015 Mar 08; 22(3):570-7. PubMed ID: 25511792
    [Abstract] [Full Text] [Related]

  • 12. Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2).
    Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Domingo-Horne R, Toukam M, Nunn A, Maghzi AH, Kuhelj R, Lasky T.
    Neurol Ther; 2024 Oct 08; 13(5):1385-1401. PubMed ID: 39046635
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
    Rabea EM, Belal MM, Hafez AH, Elbanna AH, Khalifa MA, Nourelden AZ, Mahmoud NH, Zaazouee MS.
    Acta Neurol Belg; 2024 Apr 08; 124(2):407-417. PubMed ID: 38457005
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R, Morra VB, Mirabella M, Gasperini C, Scandellari C, Totaro R, De Rossi N, Masera S, Zipoli V, Patti F, WANT Investigators.
    Neurol Sci; 2021 Jul 08; 42(7):2837-2845. PubMed ID: 33205373
    [Abstract] [Full Text] [Related]

  • 15. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun 08; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 16. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G.
    Mult Scler Relat Disord; 2017 Jan 08; 11():18-24. PubMed ID: 28104250
    [Abstract] [Full Text] [Related]

  • 17. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Thangavelu K, Robinson M, Gold R, Teri-PRO Trial Group.
    Mult Scler Relat Disord; 2018 Nov 08; 26():211-218. PubMed ID: 30273841
    [Abstract] [Full Text] [Related]

  • 18. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Trojano M, Ramió-Torrentà L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, Ren Z, Muralidharan KK, Licata S, Gafson AR.
    Mult Scler; 2021 Dec 08; 27(14):2240-2253. PubMed ID: 33821693
    [Abstract] [Full Text] [Related]

  • 19. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V, Overton ET, Mills A, Swindells S, Benn PD, Vanveggel S, van Solingen-Ristea R, Wang Y, Hudson KJ, Shaefer MS, Margolis DA, Smith KY, Spreen WR.
    Patient; 2021 Nov 08; 14(6):849-862. PubMed ID: 34056699
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Koch MW, Mostert JP, Wolinsky JS, Lublin FD, Uitdehaag B, Cutter GR.
    Neurology; 2021 Oct 19; 97(16):e1560-e1570. PubMed ID: 34433679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.